The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...

A monthly roundup of third party content produced by the Advocacy Lab, including exclusive content, expert analysis, and in-depth reports.

WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's (HIK.L), opens new tab generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular medication Vascepa did not infringe Amarin's patents, ...

After multiple hearings, witnesses tell Congress it's time to act on foreign drug quality For more than two years, we've been investigating questions about the safety of some foreign-manufactured ...

Earlier this year, Canada became the first major market in the world where generic forms of semaglutide became legal. The competition was on: Manufacturers raced to secure Health Canada approval so ...

Drugmaker Hikma’s generic version of Irish-American company Amarin Pharma’s cardiovascular medication Vascepa did not infringe ‌Amarin’s patents, the US supreme court ruled on Thursday in a decision ...

After multiple hearings, witnesses tell Congress it's time to act on foreign drug quality For more than two years, we've been investigating questions about the safety of some foreign-manufactured ...

(SOA) — What began as warnings from a handful of scientists, whistleblowers and patients has now become the subject of ongoing congressional scrutiny. In the fifth major hearing in the past year, ...

US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic ...